With over 20 years of expertise in viral vector process development, scale-up, and preclinical production, we are your trusted partner for adenovirus, AAV, and lentivirus packaging solutions.
uBriGene accelerates CGT product development by supporting early R&D and high-quality preclinical viral vector production. Leveraging our GMP expertise, we deliver top-tier vectors and comprehensive services from raw material construction to large-scale vector production.
AAV packaging platform with access to high quality raw materials to support vector process and analytical development.
View AAV Packaging ServicesProven track record in the preclincal development and production of LVV to support gene-modified cell therapy manufacturing.
View LVV Packaging ServicesPreclinical adenovirus packaging for R&D and pre-clinical studies.
Centers of Excellence for manufacturing and testing
GMP batches successfully delivered
INDs filed and accepted with FDA, EMA, and CDE
Centers of Excellence for manufacturing and testing
GMP batches successfully delivered
INDs filed and accepted with FDA, EMA, and CDE
Unveil the current manufacturing approaches for LVV and its deployment in cell therapies.
Discover our AAV manufacturing capabilities, scalable processes, and testing platform.
Learn more about how uBriGene supported oncolytic virus process development, manufacturing, and IND filing.
